Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has signed an exclusive partnership with Germany-based Formycon for the licensing and supply of a biosimilar to Keytruda (Pembrolizumab), a blockbuster cancer immunotherapy drug originally developed by Merck. The deal covers the US and Canadian markets. Keytruda is one of the world's top-selling medicines, generating tens of billions of dollars in annual sales globally. By partnering on a biosimilar version, Zydus is positioning itself in the high-value oncology biosimilars space, though the product will require regulatory approvals from the US FDA and Health Canada before it can be launched and start generating revenue.
This is a positive long-term development for Zydus, opening a potentially large revenue stream in the US and Canadian markets once the biosimilar is approved and launched. However, near-term impact on earnings is limited as biosimilar development, clinical trials, and regulatory clearances will take several years.